

Bulent Okan Yildiz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8041736/bulent-okan-yildiz-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

10,003
citations

37
h-index

99
g-index

136
ext. papers

12,211
ext. citations

4.8
avg, IF

6.13
L-index

#	Paper	IF	Citations
129	Targeting metabolism in the management of PCOS: Metformin and beyond 2022 , 117-133		
128	Investigation of taste function and eating behavior in women with polycystic ovary syndrome. <i>Appetite</i> , 2022 , 168, 105776	4.5	0
127	Impact of social isolation during COVID-19 pandemic on health behaviors and weight management in women with polycystic ovary syndrome.. <i>Eating and Weight Disorders</i> , 2022 , 1	3.6	
126	Adrenal and Polycystic Ovary Syndrome 2022 , 67-79		
125	PCOS Phenotype in Unselected Populations Study (P-PUP): Protocol for a Systematic Review and Defining PCOS Diagnostic Features with Pooled Individual Participant Data. <i>Diagnostics</i> , 2021 , 11,	3.8	1
124	Integrating Transwomen and Female Athletes with Differences of Sex Development (DSD) into Elite Competition: The FIMS 2021 Consensus Statement. <i>Sports Medicine</i> , 2021 , 51, 1401-1415	10.6	7
123	An Update on Contraception in Polycystic Ovary Syndrome. <i>Endocrinology and Metabolism</i> , 2021 , 36, 296-311	3.5	5
122	Aging versus youth: Endocrine aspects of vulnerability for COVID-19. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 1	10.5	3
121	COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. <i>Endocrine</i> , 2021 , 72, 301-316	4	29
120	Obesity and physical exercise. <i>Minerva Endocrinology</i> , 2021 , 46, 131-144	2.5	3
119	Characterization of gut microbiota in polycystic ovary syndrome: Findings from a lean population. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13417	4.6	6
118	Polycystic Ovary Syndrome and Brain: An Update on Structural and Functional Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e430-e441	5.6	3
117	Influence of ethnicity on different aspects of polycystic ovary syndrome: a systematic review. <i>Reproductive BioMedicine Online</i> , 2021 , 42, 799-818	4	2
116	Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021 , 12, 598249	5.7	16
115	Weight management strategies for patients with PCOS: current perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2021 , 16, 49-62	4.1	1
114	One year of the pandemic - how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , 2021 , 185, C1-C7	6.5	3
113	The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. <i>Maturitas</i> , 2021 , 151, 22-30	5	3

112	Publication outcome of research presented at the European Congress of Endocrinology: a web scraping-based analysis and critical appraisal. <i>Endocrine</i> , 2021 , 72, 385-391	4	0
111	Tissue fat quantification by magnetic resonance imaging: proton density fat fraction in polycystic ovary syndrome. <i>Reproductive BioMedicine Online</i> , 2020 , 41, 329-334	4	5
110	Polycystic ovary syndrome and aging: Health implications after menopause. <i>Maturitas</i> , 2020 , 139, 12-19	5	8
109	A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. <i>Diabetes Therapy</i> , 2020 , 11, 1045-1059	3.6	5
108	Cardiovascular health and menopause in aging women with polycystic ovary syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2020 , 15, 29-39	4.1	1
107	Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020 , 12, 66-71	1.7	12
106	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMd dyslipidemia study). <i>Lipids in Health and Disease</i> , 2020 , 19, 237	4.4	2
105	Glucagon-like peptide-1, a matter of taste?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 1	10.5	4
104	Gut Microbiota and Oral Contraceptive Use in Overweight and Obese Patients with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
103	Adiponectin levels decrease independently of body mass index and diabetes type after the normalization of hyperglycemia. <i>Turkish Journal of Medical Sciences</i> , 2020 , 50, 312-315	2.7	
102	Endocrinology of Hirsutism: From Androgens to Androgen Excess Disorders. <i>Frontiers of Hormone Research</i> , 2019 , 53, 108-119	3.5	7
101	Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. <i>Reproductive BioMedicine Online</i> , 2019 , 39, 522-529	4	7
100	Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMd Obesity Study). <i>Obesity Facts</i> , 2019 , 12, 167-178	5.1	15
99	Is muscle mechanical function altered in polycystic ovary syndrome?. <i>Archives of Gynecology and Obstetrics</i> , 2019 , 300, 771-776	2.5	6
98	Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2019 , 91, 810-815	3.4	13
97	MON-205 Is Muscle Mechanical Function Altered In Polycystic Ovary Syndrome?. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	1
96	Metabolic Syndrome During Menopause. <i>Current Vascular Pharmacology</i> , 2019 , 17, 595-603	3.3	11
95	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. <i>European Journal of Endocrinology</i> , 2019 , 180, P1-P22	6.5	44

94	Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. <i>Human Reproduction</i> , 2019 , 34, 2254-2265	5.7	25
93	Prevalence and predictors of gestational diabetes mellitus: a nationwide multicentre prospective study. <i>Diabetic Medicine</i> , 2019 , 36, 221-227	3.5	15
92	Prevalence of Metabolic Syndrome and Its Relation to Physical Activity and Nutrition in Azerbaijan. <i>Metabolic Syndrome and Related Disorders</i> , 2019 , 17, 160-166	2.6	4
91	Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2018 , 109, 356-364.e32	4.8	46
90	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2018 , 110, 364-379	4.8	366
89	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2018 , 89, 251-268	3.4	140
88	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Human Reproduction</i> , 2018 , 33, 1602-1618	5.7	551
87	The association of cardiorespiratory fitness, body mass index, and age with testosterone levels at screening of healthy men undergoing preventive medical examinations: The Cooper Center Longitudinal Study. <i>Maturitas</i> , 2018 , 118, 1-6	5	11
86	Turkish nationwide survey of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study). <i>Diabetes Research and Clinical Practice</i> , 2018 , 146, 138-147	7.4	16
85	Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2018 , 109, 888-899	4.8	92
84	Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2018 , 110, 523-533.e14	4.8	118
83	Structural imaging of the brain reveals decreased total brain and total gray matter volumes in obese but not in lean women with polycystic ovary syndrome compared to body mass index-matched counterparts. <i>Gynecological Endocrinology</i> , 2017 , 33, 519-523	2.4	7
82	Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. <i>Endocrine Connections</i> , 2017 , 6, 437-445	3.5	43
81	Suppressed Adiponectin Levels and Increased Adiponectin Response to Oral Glucose Load in Lean Women with Severe Acne Normalizes after Isotretinoin Treatment. <i>Dermatology</i> , 2017 , 233, 314-319	4.4	5
80	An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. <i>Hormone Research in Paediatrics</i> , 2017 , 88, 371-395	3.3	166
79	Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an update in the management of polycystic ovary syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016 , 207, 214-219	2.4	69
78	Polycystic ovary syndrome. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16057	51.1	555
77	Gut-Brain Axis and Metabolism in Polycystic Ovary Syndrome. <i>Current Pharmaceutical Design</i> , 2016 , 22, 5572-5587	3.3	15

76	Reproductive endocrinology: Contraceptives, exercise and diet - are all three needed in PCOS?. <i>Nature Reviews Endocrinology</i> , 2016 , 12, 438-40	15.2	1
75	Oxidative Stress and Periodontal Disease in Obesity. <i>Medicine (United States)</i> , 2016 , 95, e3136	1.8	39
74	Evolutionary determinants of polycystic ovary syndrome: part 1. <i>Fertility and Sterility</i> , 2016 , 106, 33-41	4.8	20
73	The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2016 , 31, 2841-2855	5.7	526
72	Approach to the patient: contraception in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 794-802	5.6	49
71	New insights into the mechanisms of diastolic dysfunction in patients with type 2 diabetes. <i>Scandinavian Cardiovascular Journal</i> , 2015 , 49, 142-8	2	3
70	Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 919-27	6.7	23
69	Comparison of adrenocortical steroidogenesis in women with post-adolescent severe acne and polycystic ovary syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 875-80	4.6	2
68	The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , 2014 , 171, P1-29	6.5	346
67	European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. <i>European Journal of Endocrinology</i> , 2014 , 171, 489-98	6.5	61
66	Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2014 , 81, 588-92	3.4	16
65	Insulin sensitivity, androgens and isotretinoin therapy in women with severe acne. <i>Journal of Dermatological Treatment</i> , 2014 , 25, 119-22	2.8	12
64	Vitamin D status and seasonal changes in plasma concentrations of 25-hydroxyvitamin D in office workers in Ankara, Turkey. <i>European Journal of Internal Medicine</i> , 2014 , 25, 197-201	3.9	25
63	Effects of L-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. <i>Archives of Medical Research</i> , 2013 , 44, 317-20	6.6	10
62	Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. <i>Contraception</i> , 2013 , 87, 358-62	2.5	39
61	Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4475-82	5.6	18
60	Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2013 , 78, 379-84	3.4	11
59	Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2013 , 78, 120-5	3.4	29

58	Combined oral contraceptives in polycystic ovary syndrome - indications and cautions. <i>Frontiers of Hormone Research</i> , 2013 , 40, 115-27	3.5	15
57	Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1088-96	5.6	100
56	Interventions for the metabolic dysfunction in polycystic ovary syndrome. <i>Steroids</i> , 2013 , 78, 777-81	2.8	13
55	Effects of L-thyroxine on gastric motility and ghrelin in subclinical hypothyroidism: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1775-9	5.6	5
54	Polycystic ovary syndrome: is obesity a symptom?. <i>Women's Health</i> , 2013 , 9, 505-7	3	9
53	The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 193-200	2.3	19
52	Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy. <i>Medical Science Monitor</i> , 2013 , 19, 210-5	3.2	18
51	25-OH-Vitamin D and procalcitonin levels after correction of acute hyperglycemia. <i>Medical Science Monitor</i> , 2013 , 19, 264-8	3.2	7
50	Consensus on women's health aspects of polycystic ovary syndrome (PCOS). <i>Human Reproduction</i> , 2012 , 27, 14-24	5.7	223
49	Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. <i>Human Reproduction</i> , 2012 , 27, 3067-73	5.7	359
48	Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. <i>Fertility and Sterility</i> , 2012 , 97, 28-38.e23	4.8	1195
47	Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome. <i>Journal of Ovarian Research</i> , 2012 , 5, 42	5.5	6
46	Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception. <i>Human Reproduction Update</i> , 2012 , 18, 670-81	15.8	10
45	Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. <i>Human Reproduction</i> , 2012 , 27, 1840-5	5.7	46
44	Periodontal disease in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2011 , 95, 320-3	4.8	36
43	PCOS Forum: research in polycystic ovary syndrome today and tomorrow. <i>Clinical Endocrinology</i> , 2011 , 74, 424-33	3.4	102
42	Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. <i>Human Reproduction</i> , 2011 , 26, 3339-45	5.7	88
41	Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. <i>Clinical Endocrinology</i> , 2010 , 72, 469-74	3.4	21

40	Insulin resistance in polycystic ovary syndrome: maker or marker?. <i>Expert Review of Obstetrics and Gynecology</i> , 2010 , 5, 67-75		3
39	Visually scoring hirsutism. <i>Human Reproduction Update</i> , 2010 , 16, 51-64	15.8	198
38	Increased circulating soluble P-selectin in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2010 , 93, 2311-8	14.8	14
37	Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society. <i>Fertility and Sterility</i> , 2010 , 94, 690-3	4.8	14
36	Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. <i>Reproductive BioMedicine Online</i> , 2010 , 20, 150-5	4	37
35	Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor- α . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 935-42	5.6	36
34	Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. <i>Seminars in Reproductive Medicine</i> , 2008 , 26, 111-20	1.4	42
33	Assessment, diagnosis and treatment of a patient with hirsutism. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, 294-300		8
32	Impact of obesity on the risk for polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 162-8	5.6	230
31	Autoimmune polyendocrine syndrome with atrial septal defect. <i>American Journal of the Medical Sciences</i> , 2008 , 335, 157-9	2.2	1
30	Impact of Diagnostic Criteria 2008 , 333-344		1
29	Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. <i>American Journal of Obstetrics and Gynecology</i> , 2007 , 196, 398.e1-5; discussion 398.e5-6	6.4	12
28	The adrenal and polycystic ovary syndrome. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007 , 8, 331-42	10.5	83
27	The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. <i>PPAR Research</i> , 2007 , 2007, 49109	4.3	48
26	Effects of leptin on intake of specific micro- and macronutrients in a woman with leptin gene deficiency studied off and on leptin at stable body weight. <i>Appetite</i> , 2007 , 49, 594-9	4.5	24
25	Hormonal and Biochemical Evaluation of Polycystic Ovary Syndrome 2007 , 241-248		1
24	Prevalence of glutamic acid decarboxylase antibody positivity and its association with insulin secretion and sensitivity in autoimmune thyroid disease: A pilot study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006 , 114, 412-6	2.3	8
23	Diagnosis of hyperandrogenism: clinical criteria. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2006 , 20, 167-76	6.5	70

22	Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters. <i>Fertility and Sterility</i> , 2006 , 86, 1688-93	4.8	28
21	Rethinking leptin and insulin action: therapeutic opportunities for diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2006 , 38, 820-30	5.6	44
20	Hypothalamic-Pituitary-Adrenal Dysfunction in the Polycystic Ovary Syndrome 2006 , 213-222		
19	Polycystic Ovary Syndrome and Ovulation Induction 2006 , 389-404		
18	Masking Effect of Endogenous Hypercortisolism on Vasculitis 2005 , 15, 281-285		
17	Effect of leptin replacement on brain structure in genetically leptin-deficient adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2851-4	5.6	151
16	Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5558-62	5.6	25
15	Simultaneous and continuous 24-hour plasma and cerebrospinal fluid leptin measurements: dissociation of concentrations in central and peripheral compartments. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 258-65	5.6	28
14	Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 4531-6	11.5	390
13	Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10434-9	11.5	269
12	An experimental therapeutic approach to genetically-based obesity leptin replacement therapy resolves morbid obesity, hypogonadism and diabetes mellitus in leptin-deficient adults. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P11	6.1	
11	A patient presenting with spinal cord compression who had two distinct follicular cell type thyroid carcinomas. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 562-4	5.2	2
10	Recent advances in the treatment of polycystic ovary syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 1295-305	5.9	9
9	Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome. <i>Reproductive BioMedicine Online</i> , 2004 , 8, 649-56	4	14
8	The prevalence and features of the polycystic ovary syndrome in an unselected population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2745-9	5.6	1849
7	Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2031-6	5.6	184
6	Metformin and FSH for induction of ovulation in women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2002 , 17, 3007-8	5.7	3
5	Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3871-5	5.6	107

4	Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. <i>Human Reproduction</i> , 2002 , 17, 289-94	5.7	138
3	Adrenocortical dysfunction in polycystic ovary syndrome 2001 , 288-315		
2	Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2001 , 100, 62-6	2.4	16
1	Albendazole-induced amegakaryocytic thrombocytopenic purpura. <i>Annals of Pharmacotherapy</i> , 1998 , 32, 842	2.9	6